Traws Pharma, Inc.
TRAWHealthcare|Biotechnology|US
$0.22
+0.00 (+0.82%)
Cash / Share
$0.29
Financials
Financial Snapshot
Market Cap
$3.4M
Enterprise Value
$277.2K
Revenue (TTM)
$2.8M
Net Income (TTM)
-$19.9M
Cash & Investments
$3.1M
Net Cash
$3.1M
Free Cash Flow (TTM)
-$15.4M
Operating CF (TTM)
-$15.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$3.1M
Quarterly Burn
$3.8M
Monthly Burn
$1.3M
Est. Runway
~0.8 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $21.4M | $4.0M | $17.0M | $22.7M | $19.0M | $55.1M | $38.8M | $20.8M | $21.3M | $3.8M | $3.1M | |
| Operating Cash Flow | -$15.8M | -$23.8M | -$22.7M | -$20.8M | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$18.2M | -$15.4M | |
| Free Cash Flow | -$15.8M | -$23.8M | -$22.7M | -$20.9M | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$20.8M | -$15.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$55.0K | -$15.0K | $0.00 | $0.00 | -$14.0K | $0.00 | -$2.6M | $0.00 | |
| Financing Cash Flow | $17.4M | $6.4M | $35.7M | $26.6M | $19.4M | $55.6M | $0.00 | $0.00 | $34.0M | $3.2M | $25.1M |
R&D Spending
R&D (TTM)
$17.3M
R&D Intensity
621.8%
R&D Growth vs Prior
+42.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $787.0K | $1.2M | $2.2M | $231.0K | $226.0K | $226.0K | $226.0K | $226.0K | $2.8M | $2.8M | |
| R&D Expense | $20.1M | $19.0M | $16.9M | $15.5M | $16.9M | $7.3M | $11.4M | $11.4M | $130.3M | $12.1M | $17.3M | |
| R&D % of Revenue | 361.9% | 2418.2% | 1373.7% | 711.7% | 7315.2% | 3228.8% | 5046.9% | 5057.5% | 57659.7% | 435.2% | 621.8% | |
| SG&A | $9.1M | $7.4M | $7.6M | $8.3M | $8.3M | $9.4M | $8.4M | $9.1M | $12.3M | $8.5M | $9.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $787.0K | $1.2M | $2.2M | $231.0K | $226.0K | $226.0K | $226.0K | $226.0K | $2.8M | $2.8M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $12.0K | $0.00 | $2.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $2.2M | $231.0K | $226.0K | $226.0K | $226.0K | $214.0K | $2.8M | $2.8M | |
| R&D | $20.1M | $19.0M | $16.9M | $15.5M | $16.9M | $7.3M | $11.4M | $11.4M | $130.3M | $12.1M | $17.3M | |
| SG&A | $9.1M | $7.4M | $7.6M | $8.3M | $8.3M | $9.4M | $8.4M | $9.1M | $12.3M | $8.5M | $9.5M | |
| Operating Income | -$23.7M | -$25.7M | -$23.3M | -$21.7M | -$25.0M | -$16.5M | -$19.6M | -$20.3M | -$49.3M | -$17.9M | -$24.1M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$19.7M | -$24.1M | -$20.5M | -$21.5M | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$166.5M | $9.2M | -$23.9M | |
| Net Income | -$19.7M | -$24.1M | -$20.6M | -$21.5M | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$54.7M | $9.2M | -$19.9M | |
| EPS (Diluted) | -24975.00 | -15056.00 | -1870.69 | -560.58 | -54.21 | -24.01 | -22.68 | -22.57 | -35.21 | 0.82 | -9.42 | |
| EBITDA | -$19.6M | -$24.0M | -$20.5M | -$21.7M | -$25.0M | -$16.5M | -$19.6M | -$20.3M | -$166.5M | -$17.8M | -$23.9M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.01 | 0.04 | 0.46 | 0.67 | 0.84 | 0.84 | 1.55 | 8.38 | 10.64 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.4M | $4.0M | $17.0M | $22.7M | $19.0M | $55.1M | $38.8M | $20.8M | $21.3M | $3.8M | $3.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $23.1M | $4.9M | $17.8M | $23.5M | $19.8M | $55.4M | $39.3M | $22.7M | $25.0M | $8.0M | $5.7M | |
| Total Assets | $23.2M | $5.0M | $17.9M | $23.7M | $20.0M | $55.5M | $39.4M | $22.7M | $25.0M | $10.6M | $8.2M | |
| Total Current Liabilities | $10.2M | $10.0M | $8.4M | $8.3M | $10.0M | $6.1M | $8.0M | $9.2M | $11.5M | $11.1M | $13.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $18.1M | $15.8M | $12.5M | $12.1M | $13.8M | $9.4M | $11.1M | $12.0M | $56.6M | $11.2M | $13.5M | |
| Stockholders' Equity | $4.3M | -$11.7M | $5.4M | $11.6M | $6.2M | $46.1M | $28.3M | $10.7M | -$31.6M | -$629.0K | -$5.3M | |
| Retained Earnings | -$338.2M | -$362.3M | -$381.9M | -$403.4M | -$428.6M | -$444.7M | -$463.7M | -$482.6M | -$649.2M | -$640.0M | -$647.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.8M | -$23.8M | -$22.7M | -$20.8M | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$18.2M | -$15.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$55.0K | -$15.0K | $0.00 | $0.00 | -$14.0K | $0.00 | -$2.6M | $0.00 | |
| Free Cash Flow | -$15.8M | -$23.8M | -$22.7M | -$20.9M | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$20.8M | -$15.4M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | -$55.0K | -$15.0K | $0.00 | $0.00 | -$14.0K | -$3.6M | -$2.6M | $0.00 | |
| Financing Cash Flow | $17.4M | $6.4M | $35.7M | $26.6M | $19.4M | $55.6M | $0.00 | $0.00 | $34.0M | $3.2M | $25.1M | |
| Issuance of Stock | $17.4M | $6.4M | $35.1M | $21.8M | $9.1M | $55.0M | $0.00 | $0.00 | $34.0M | $5.6M | $30.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.4M | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $576.0K | $1.2M | $1.3M | $0.00 | $728.0K | $961.0K | |
| Net Change in Cash | $1.6M | -$17.4M | $12.9M | $5.8M | -$3.7M | $36.0M | -$16.3M | -$17.9M | $517.0K | -$17.5M | $9.8M |
Dilution Tracker
Shares outstanding grew 1704.9% over 5 years — significant dilution
Shares Outstanding
15M
5-Year Share Growth
+1704.9%
Stock Issuance (TTM)
$30.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.01 | 0.04 | 0.46 | 0.67 | 0.84 | 0.84 | 1.55 | 8.38 | 10.64 | |
| Change vs Prior % | — | 103.3% | 587.3% | 248.8% | 1109.9% | 45.1% | 24.2% | 0.4% | 84.9% | 439.5% | 27.0% | |
| Stock Issuance | $17.4M | $6.4M | $35.1M | $21.8M | $9.1M | $55.0M | $0.00 | $0.00 | $34.0M | $5.6M | $30.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.4M | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $576.0K | $1.2M | $1.3M | $0.00 | $728.0K | $961.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.7% | 100.0% | 99.9% | |
| Operating Margin % | -427.4% | -3270.3% | -1895.9% | -994.0% | -10819.5% | -7299.1% | -8684.5% | -8981.4% | -21835.4% | -640.7% | -863.8% | |
| Net Margin % | -354.6% | -3061.2% | -1675.3% | -985.0% | -10890.5% | -7151.8% | -8391.2% | -8384.1% | -24192.0% | 328.7% | -712.8% | |
| EBITDA Margin % | -352.6% | -3048.4% | -1667.7% | -993.4% | -10813.9% | -7292.9% | -8678.3% | -8974.3% | -73677.4% | -638.5% | -858.3% | |
| FCF Margin % | -285.1% | -3026.7% | -1848.2% | -956.8% | -9995.7% | -8622.6% | -7209.7% | -7940.7% | -13182.3% | -744.4% | -550.3% | |
| ROE % | -457.7% | 206.1% | -381.9% | -185.8% | -407.4% | -35.0% | -67.0% | -177.5% | 172.9% | -1457.9% | 353.4% | |
| ROA % | -84.7% | -483.9% | -114.8% | -90.8% | -125.9% | -29.1% | -48.2% | -83.5% | -219.0% | 86.4% | -128.7% | |
| ROIC % | -181.3% | 515.0% | -244.0% | -141.1% | -250.8% | -33.4% | -62.7% | -150.8% | -367.5% | 3379.0% | 283.3% | |
| R&D / Revenue % | 361.9% | 2418.2% | 1373.7% | 711.7% | 7315.2% | 3228.8% | 5046.9% | 5057.5% | 57659.7% | 435.2% | 621.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -51.6% | -85.8% | 56.0% | 77.8% | -89.4% | -2.2% | 0.0% | 0.0% | 0.0% | 1134.5% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | -89.4% | -2.2% | 0.0% | 0.0% | -5.3% | 1203.7% | |
| Operating Income | 1.1% | -8.6% | 9.5% | 6.8% | -15.2% | 34.0% | -19.0% | -3.4% | -143.1% | 63.8% | |
| Net Income | 18.0% | -22.5% | 14.6% | -4.5% | -17.0% | 35.8% | -17.3% | 0.1% | -188.5% | 116.8% | |
| EPS (Diluted) | 57.7% | 39.7% | 87.6% | 70.0% | 90.3% | 55.7% | 5.5% | 0.5% | -56.0% | 102.3% | |
| Operating Cash Flow | 49.5% | -50.6% | 4.7% | 8.2% | -10.8% | 15.5% | 16.4% | -10.1% | -66.1% | 39.0% | |
| Free Cash Flow | 49.5% | -50.6% | 4.7% | 8.0% | -10.6% | 15.6% | 16.4% | -10.1% | -66.0% | 30.3% | |
| R&D Expense | -22.5% | -5.2% | -11.4% | -7.9% | 8.8% | -56.8% | 56.3% | 0.2% | 1040.1% | -90.7% | |
| SG&A Expense | -3.2% | -18.5% | 2.4% | 10.0% | -0.2% | 13.2% | -10.4% | 7.7% | 35.1% | -30.7% | |
| Total Assets | -0.9% | -78.6% | 260.0% | 32.1% | -15.6% | 177.6% | -29.0% | -42.4% | 10.0% | -57.5% | |
| Book Value / Share | -75.7% | -204.2% | 107.2% | -38.4% | -95.6% | 414.8% | -50.6% | -62.4% | -260.3% | 99.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 94.8% | 103.3% | 587.3% | 248.8% | 1109.9% | 45.1% | 24.2% | 0.4% | 84.9% | 439.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High1.81 / 60.13 / 354.10
P/B-0.44
10Y Low / Med / High0.47 / 1.48 / 13.25
EV/EBITDAAt Loss
10Y Low / Med / High0.05 / 0.58 / 1.28
EV/Revenue0.00
10Y Low / Med / High1.96 / 12.04 / 271.74
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.29
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.51 | -0.56 | -0.42 | -0.25 | -3.25 | -2.66 | -0.72 | -0.83 | -0.25 | 1.36 | -0.44 | |
| P/S Ratio | 1.81 | 17.15 | 7.09 | 2.50 | 354.10 | 189.92 | 60.13 | 69.65 | 61.01 | 3.33 | 0.00 | |
| P/B Ratio | 2.34 | -1.15 | 1.62 | 0.47 | 13.25 | 0.93 | 0.48 | 1.48 | -0.44 | -14.78 | -0.44 | |
| EV/EBITDA | 0.58 | -0.39 | 0.40 | 0.80 | -2.51 | 0.74 | 1.28 | 0.25 | 0.05 | -0.31 | -0.02 | |
| EV/Revenue | -2.06 | 12.04 | -6.73 | -7.91 | 271.74 | -53.75 | -111.36 | -22.48 | -33.41 | 1.96 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-117.82
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $300.0K | $13.1M | $55.4M |
| Net Income | -$10.1M | -$10.3M | -$5.0M |
| EPS | $-1.20 | $-1.24 | $-0.60 |
| # Analysts (EPS) | 1 | 1 | 1 |